Effect of 4 Weeks Treatment With Acipimox in Patients With Chronic Heart Failure
NCT ID: NCT00549614
Last Updated: 2009-10-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
28 participants
INTERVENTIONAL
2007-10-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Metabolic Modulation as Treatment in Acute Heart Failure
NCT00449423
Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention
NCT05241431
Effects of Acetazolamide and CO2 Inhalation on Exercise-induced Periodic Breathing in Heart Failure
NCT00517426
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL180
NCT00907998
Phase Ib/IIa Trial With AC01 in Patients With HFrEF
NCT05642507
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
acipimox
capsule, 250 mg, 4 times daily for 28 days
2
placebo
capsule, 250 mg, 4 times daily for 28 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acipimox
capsule, 250 mg, 4 times daily for 28 days
placebo
capsule, 250 mg, 4 times daily for 28 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* IHD
* NYHA-class II-III.
Exclusion Criteria
* severe renal failure
* new brady- or tachyArrhythmia
* Severe stenotic valvular disease
* myocardial infarction within last 6 weeks
* insulin treated diabetes mellitus
* peptic ulcer
* pregnancy or lactating women
* allergy towards tested medicine
30 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Aarhus
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Cardiology, Aarhus Universityhospital, Skejby
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mads Halbirk
Role: PRINCIPAL_INVESTIGATOR
B-research, Aarhus Universityhospital, skejby
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Aarhus Universityhospital, Skejby
Aarhus N, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20061218
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.